Black Hawk shareholders approve Vesicor Therapeutics merger; 2.09M shares redeemed at $12.04

Black Hawk Acquisition Corp

All eight proposals passed at the October 13, 2026 extraordinary general meeting, including the Business Combination Agreement dated April 26, 2025 with Vesicor Therapeutics, Inc.
Business Combination vote: 3,191,351 for, 20,165 against, 0 abstentions; about 77.3% of 4,153,577 outstanding shares present, constituting a quorum.
Five post-closing directors elected: Luo Feng, Warren Hosseinion, Frederick Woodruff Field, Oded Levy and Qi Ouyang.
2,089,162 ordinary shares redeemed for $25,153,510.48 total, a per-share price of about $12.04; the Company is not permitting reversals of redemption elections.
Other approvals: Cayman-to-Delaware domestication, new charter/bylaws, Nasdaq share issuance, Vesicor 2026 Equity Incentive Plan, and removal of the $5,000,001 net tangible asset condition.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.